Otros idiomas BenevolentAI

Acciones

BAI

LU2355630455

Mercado cerrado - Euronext Amsterdam Otros sitios de cotización 17:35:27 30/04/2024			Varia. Cinco días.	Varia. 1 de enero.
0,64 ^EUR	-3,03 %		-4,48 %	-40,74 %

15/04	BenevolentAI S.A. anuncia la dimisión de sus miembros del Consejo de Administración, con efecto a partir del 2 de mayo de 2024	CI
02/04	Kenneth Mulvany envía una carta a Benovelent AI	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

BenevolentAI : Major shareholding notifications Major shareholding notification	01/05
BenevolentAI : Benevolent AI, - BenevolentAI provides an update on its business priorities	23/04
BenevolentAI Provides an Update on Its Business Priorities	23/04
BenevolentAI - Publication of the Revised Agenda for the 2024 AGM	18/04
BenevolentAI : Benevolent AI, - Publication of the Revised Agenda for the 2024 AGM	17/04
BenevolentAI : Inside Information / Ad Hoc Information Publication of the Revised Agenda for the 2024 AGM	17/04
BenevolentAI: Publication of the Revised Agenda for the 2024 AGM	17/04
Proposed changes to BenevolentAI's Board composition	16/04
Proposed Changes to BenevolentAI’s Board Composition	15/04
BenevolentAI S.A. Announces Board Resignations, Effective from May 2, 2024	15/04
BenevolentAI Founder Reportedly Calls for Board Revamp	03/04
BenevolentAI Founder Reportedly Calls for Board Revamp	02/04
Kenneth Mulvany Sends a Letter to Benovelent AI	02/04
EARNINGS: EPE Special "cautiously optimistic"; RTW Biotech NAV rises	02/04
BenevolentAI : Inside Information / Ad Hoc Information BenevolentAI announces positive topline safety and pharmacokinetic data from the Phase Ia clinical study of BEN-8744 in healthy volunteers	25/03
BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers	25/03
BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers	25/03
Benevolent AI CEO discusses 2023 highlights and 2024 outlook as it pioneers AI in drug discovery	21/03
BenevolentAI : Benevolent AI, - Publication of 2023 Annual Report and 2024 AGM Notice	20/03
BenevolentAI : Inside Information / Ad Hoc Information Publication of 2023 Annual Report and 2024 AGM Notice	20/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas BenevolentAI

Acciones

BAI

LU2355630455

Otros idiomas

Filtros